MESOBLAST LIMITED - Announcements

Market Cap $1.364B Add to my watchlist

Healthcare Biotechnology

Mesoblast Limited is an Australia-based company, which is engaged in developing... Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.More

RCE'S BREAKTHROUGH

Synthetic anti-infective developer Recce Pharmaceuticals Ltd (ASX:RCE) has made inroads for recognition of its RECCE® 327 Gel (or R327G) as a topical treatment for burn wound infections, gaining a US$2 million grant from the US Department of Defense...

Announcements

Filter Results

All Price Sensitive Only

MSB	Second Quarter Results Presentation	PRICE SENSITIVE	25/02/22	2.82MB	Share
MSB	Half Yearly Report and Accounts	PRICE SENSITIVE	25/02/22	948.77KB	Share
MSB	Mesoblast Q2 Financial Results Webcast		24/02/22	114.99KB	Share
MSB	Ulcerative Colitis & Crohns Results Presented at ECCO	PRICE SENSITIVE	21/02/22	192.81KB	Share
MSB	Mesoblast Appoints Dr Eric Rose as Chief Medical Officer		02/02/22	193.54KB	Share
MSB	Appendix 4C Quarterly Activity Report	PRICE SENSITIVE	31/01/22	340.86KB	Share
MSB	MSB Presents at Edison Group Global Healthcare Conference		25/01/22	146.79KB	Share
MSB	Cleansing Notice and Appendix 2A		18/01/22	489.88KB	Share
MSB	Proposed issue of securities - MSB		18/01/22	26.45KB	Share
MSB	Appendix 3G, Appendix 3H and Appendix 3Y		17/01/22	543.81KB	Share
MSB	36-Month Results of Phase 3 Trial in Chronic Low Back Pain		12/01/22	158.05KB	Share
MSB	Biotech Showcase 2022 Presentation		12/01/22	3.36MB	Share
MSB	Prospectus for Warrants Related to Oaktree Debt Refinance		06/01/22	585.47KB	Share
MSB	Update on FDA Meeting for Remestemcel-L in Paediatric GvHD		31/12/21	178.48KB	Share
MSB	FDAs OTAT Agrees to Primary Endpoint for Back Pain	PRICE SENSITIVE	16/12/21	171.73KB	Share
MSB	Update on Novartis Agreement	PRICE SENSITIVE	14/12/21	129.26KB	Share
MSB	Pause in Trading	PRICE SENSITIVE	14/12/21	116.22KB	Share
MSB	Rexlemestrocel Greatest Benefit in Diabetics and Ischemics		06/12/21	226.31KB	Share
MSB	Global CardioVascular Clinical Trialists Forum Presentation		06/12/21	1.65MB	Share
MSB	Results of Meeting		29/11/21	153.78KB	Share
MSB	CEO Presentation to 2021 Annual General Meeting		29/11/21	3.74MB	Share
MSB	Mesoblast Chairman Message to 2021 AGM		29/11/21	210.29KB	Share
MSB	MSB Q1 Financial Results and Operational Highlights	PRICE SENSITIVE	24/11/21	563.41KB	Share
MSB	First Quarter Results Presentation		24/11/21	3.53MB	Share
MSB	First Quarter Financial Results on Form 6-K	PRICE SENSITIVE	24/11/21	518.14KB	Share
MSB	Mesoblast Q1 Financial Results Webcast		23/11/21	123.05KB	Share
MSB	MSB and Oaktree Conclude Refinancing of Senior Debt Facility	PRICE SENSITIVE	22/11/21	133.88KB	Share
MSB	Proposed issue of securities - MSB		22/11/21	26.75KB	Share
MSB	AHA Late-Breaker - Rexlemestrocel Improves Cardiac Outcomes	PRICE SENSITIVE	15/11/21	205.61KB	Share
MSB	Annual Report to Shareholders		29/10/21	3.87MB	Share
MSB	Notice of Annual General Meeting and Proxy Form		29/10/21	1.83MB	Share
MSB	Appendix 4G and Corporate Governance Statement		29/10/21	357.9KB	Share
MSB	Appendix 4C Quarterly Activity Report	PRICE SENSITIVE	29/10/21	345.66KB	Share
MSB	Remestemcel-L Improves Survival in High-Risk Acute GvHD		18/10/21	189.84KB	Share
MSB	Notification of cessation of securities - MSB		14/10/21	21.63KB	Share
MSB	Notification regarding unquoted securities - MSB		14/10/21	24.54KB	Share
MSB	CHF Late Breaker Presentation at American Heart Association		07/10/21	160.39KB	Share
MSB	MSB Annual Financial Results and Operational Progress	PRICE SENSITIVE	31/08/21	632.34KB	Share
MSB	Annual Financial Results Presentation		31/08/21	3.21MB	Share
MSB	Preliminary Final Report including Appendix 4E	PRICE SENSITIVE	31/08/21	2.73MB	Share
MSB	Appendix 3G and 3H		30/08/21	422.3KB	Share
MSB	Mesoblast 2021 Full Year Financial Results Webcast		30/08/21	124.73KB	Share
MSB	Mesoblast Management Update		10/08/21	130.38KB	Share
MSB	Appendix 4C Quarterly Activity Report	PRICE SENSITIVE	30/07/21	349.24KB	Share
MSB	Release of Shares from Voluntary Escrow		29/07/21	100.85KB	Share
MSB	COVID ARDS Trial 90-Day Survival Outcomes Presented at ISCT		19/07/21	178.27KB	Share
MSB	COVID ARDS Trial Respiratory Outcomes Presented		16/07/21	168.08KB	Share
MSB	COVID ARDS Trial Results Presentation		16/07/21	2.87MB	Share
MSB	Appendix 3Y - Change of Director's Interest Notice		14/07/21	279.52KB	Share
MSB	Appendix 3G		07/07/21	382.66KB	Share
MSB	Mesoblast Update on Chronic Low Back Pain Program	PRICE SENSITIVE	01/07/21	181.33KB	Share
MSB	MSB Reports Q3 Financial Results and Operational Highlight	PRICE SENSITIVE	03/06/21	479.65KB	Share
MSB	Third Quarter Results Presentation		03/06/21	2.01MB	Share
MSB	Third Quarter Financial Results on Form 6-K	PRICE SENSITIVE	03/06/21	633.63KB	Share
MSB	Mesoblast Q3 Financial Results Webcast		03/06/21	128.45KB	Share
MSB	Remestemcel-L for COPD Published in Respiratory Research		25/05/21	167.73KB	Share
MSB	COVID ARDS Trial Topline 60-Day Results	PRICE SENSITIVE	30/04/21	191.36KB	Share
MSB	Appendix 4C Quarterly Activity Report	PRICE SENSITIVE	30/04/21	368.8KB	Share
MSB	Mesoblast Corporate Update Webcast		30/04/21	151.83KB	Share
MSB	Director's Interest Notice - Appendix 3X		06/04/21	218.38KB	Share
MSB	Mesoblast Operational Highlights and Upcoming Milestones		31/03/21	198.71KB	Share
MSB	Director Appointment/Resignation		29/03/21	172.63KB	Share
MSB	Prospectus for Warrants in Connection with US$110M Raise		15/03/21	572.99KB	Share
MSB	MSB Closes US$110M Raise Led By US Strategic Investor Group		09/03/21	190.16KB	Share
MSB	Cleansing Notice and Appendix 2A		09/03/21	438.01KB	Share
MSB	Cleansing Notice and Appendix 2A		03/03/21	525.01KB	Share
MSB	Proposed issue of Securities - MSB		02/03/21	27.96KB	Share
MSB	Mesoblast Raises US$110M Led By US Strategic Investor Group	PRICE SENSITIVE	02/03/21	195.87KB	Share
MSB	Half Year Report and Accounts (including Appendix 4D)	PRICE SENSITIVE	26/02/21	806.09KB	Share
MSB	Trading Halt	PRICE SENSITIVE	26/02/21	206.93KB	Share
MSB	Remestemcel-L for COVID-19 MIS-C published in Pediatrics		17/02/21	192.67KB	Share
MSB	Mesoblast Phase 3 Chronic Low Back Pain Results	PRICE SENSITIVE	11/02/21	360.41KB	Share
MSB	Mesoblast Corporate Update Webcast		11/02/21	178.83KB	Share
MSB	Appendix 4C Quarterly Activity Report	PRICE SENSITIVE	29/01/21	209.47KB	Share
MSB	CHF Phase 3 Trial Results Presented at Investor Conference		12/01/21	120.14KB	Share
MSB	Mesoblast Healthcare Conference Investor Presentation		12/01/21	1.59MB	Share
MSB	Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF	PRICE SENSITIVE	11/01/21	126.77KB	Share
MSB	Mesoblast Webcast		18/12/20	106.41KB	Share
MSB	Mesoblast Update on COVID-19 ARDS Trial	PRICE SENSITIVE	18/12/20	106.84KB	Share
MSB	Trading halt	PRICE SENSITIVE	16/12/20	155.18KB	Share
MSB	Pause in Trading	PRICE SENSITIVE	16/12/20	116.28KB	Share
MSB	Mesoblast Phase 3 Chronic Heart Failure Results	PRICE SENSITIVE	15/12/20	130.08KB	Share
MSB	Mesoblast Corporate Update Webcast		15/12/20	105.09KB	Share
MSB	Remestemcel-L Reduces Biomarkers for Mortality in SR-aGVHD		07/12/20	146.6KB	Share
MSB	Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS	PRICE SENSITIVE	02/12/20	116.21KB	Share
MSB	Appendix 2A		27/11/20	167.16KB	Share
MSB	Results of Meeting		24/11/20	208.38KB	Share
MSB	CEO Presentation to 2020 Annual General Meeting		24/11/20	1.7MB	Share
MSB	Mesoblast Chairman Message to 2020 AGM		24/11/20	113.7KB	Share
MSB	Novartis and Mesoblast Remestemcel-L Collaboration	PRICE SENSITIVE	20/11/20	147.21KB	Share
MSB	First Quarter Results Presentation	PRICE SENSITIVE	20/11/20	2.18MB	Share
MSB	MSB Q1 Financial Results and Operational Highlights	PRICE SENSITIVE	20/11/20	271.6KB	Share
MSB	First Quarter Financial Results on Form 6-K	PRICE SENSITIVE	20/11/20	590.73KB	Share
MSB	Mesoblast Corporate Update and Financial Results Webcast		20/11/20	81.67KB	Share
MSB	DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial	PRICE SENSITIVE	11/11/20	117.63KB	Share
MSB	COVID-19 ARDS & GVHD Update, Quarterly Report & Appendix 4C	PRICE SENSITIVE	29/10/20	192.37KB	Share
MSB	Annual Report to shareholders		26/10/20	3.05MB	Share
MSB	Notice of Annual General Meeting and Proxy Form		26/10/20	357.21KB	Share
MSB	Appendix 4G and Corporate Governance Statement		26/10/20	202.52KB	Share
MSB	Remestemcel Controlled Study in Crohns & Ulcerative Colitis		22/10/20	126.07KB	Share

MSB Second Quarter Results Presentation
25/02/22	PRICE SENSITIVE	2.82MB	Share
MSB Half Yearly Report and Accounts
25/02/22	PRICE SENSITIVE	948.77KB	Share
MSB Mesoblast Q2 Financial Results Webcast
24/02/22		114.99KB	Share
MSB Ulcerative Colitis & Crohns Results Presented at ECCO
21/02/22	PRICE SENSITIVE	192.81KB	Share
MSB Mesoblast Appoints Dr Eric Rose as Chief Medical Officer
02/02/22		193.54KB	Share
MSB Appendix 4C Quarterly Activity Report
31/01/22	PRICE SENSITIVE	340.86KB	Share
MSB MSB Presents at Edison Group Global Healthcare Conference
25/01/22		146.79KB	Share
MSB Cleansing Notice and Appendix 2A
18/01/22		489.88KB	Share
MSB Proposed issue of securities - MSB
18/01/22		26.45KB	Share
MSB Appendix 3G, Appendix 3H and Appendix 3Y
17/01/22		543.81KB	Share
MSB 36-Month Results of Phase 3 Trial in Chronic Low Back Pain
12/01/22		158.05KB	Share
MSB Biotech Showcase 2022 Presentation
12/01/22		3.36MB	Share
MSB Prospectus for Warrants Related to Oaktree Debt Refinance
06/01/22		585.47KB	Share
MSB Update on FDA Meeting for Remestemcel-L in Paediatric GvHD
31/12/21		178.48KB	Share
MSB FDAs OTAT Agrees to Primary Endpoint for Back Pain
16/12/21	PRICE SENSITIVE	171.73KB	Share
MSB Update on Novartis Agreement
14/12/21	PRICE SENSITIVE	129.26KB	Share
MSB Pause in Trading
14/12/21	PRICE SENSITIVE	116.22KB	Share
MSB Rexlemestrocel Greatest Benefit in Diabetics and Ischemics
06/12/21		226.31KB	Share
MSB Global CardioVascular Clinical Trialists Forum Presentation
06/12/21		1.65MB	Share
MSB Results of Meeting
29/11/21		153.78KB	Share
MSB CEO Presentation to 2021 Annual General Meeting
29/11/21		3.74MB	Share
MSB Mesoblast Chairman Message to 2021 AGM
29/11/21		210.29KB	Share
MSB MSB Q1 Financial Results and Operational Highlights
24/11/21	PRICE SENSITIVE	563.41KB	Share
MSB First Quarter Results Presentation
24/11/21		3.53MB	Share
MSB First Quarter Financial Results on Form 6-K
24/11/21	PRICE SENSITIVE	518.14KB	Share
MSB Mesoblast Q1 Financial Results Webcast
23/11/21		123.05KB	Share
MSB MSB and Oaktree Conclude Refinancing of Senior Debt Facility
22/11/21	PRICE SENSITIVE	133.88KB	Share
MSB Proposed issue of securities - MSB
22/11/21		26.75KB	Share
MSB AHA Late-Breaker - Rexlemestrocel Improves Cardiac Outcomes
15/11/21	PRICE SENSITIVE	205.61KB	Share
MSB Annual Report to Shareholders
29/10/21		3.87MB	Share
MSB Notice of Annual General Meeting and Proxy Form
29/10/21		1.83MB	Share
MSB Appendix 4G and Corporate Governance Statement
29/10/21		357.9KB	Share
MSB Appendix 4C Quarterly Activity Report
29/10/21	PRICE SENSITIVE	345.66KB	Share
MSB Remestemcel-L Improves Survival in High-Risk Acute GvHD
18/10/21		189.84KB	Share
MSB Notification of cessation of securities - MSB
14/10/21		21.63KB	Share
MSB Notification regarding unquoted securities - MSB
14/10/21		24.54KB	Share
MSB CHF Late Breaker Presentation at American Heart Association
07/10/21		160.39KB	Share
MSB MSB Annual Financial Results and Operational Progress
31/08/21	PRICE SENSITIVE	632.34KB	Share
MSB Annual Financial Results Presentation
31/08/21		3.21MB	Share
MSB Preliminary Final Report including Appendix 4E
31/08/21	PRICE SENSITIVE	2.73MB	Share
MSB Appendix 3G and 3H
30/08/21		422.3KB	Share
MSB Mesoblast 2021 Full Year Financial Results Webcast
30/08/21		124.73KB	Share
MSB Mesoblast Management Update
10/08/21		130.38KB	Share
MSB Appendix 4C Quarterly Activity Report
30/07/21	PRICE SENSITIVE	349.24KB	Share
MSB Release of Shares from Voluntary Escrow
29/07/21		100.85KB	Share
MSB COVID ARDS Trial 90-Day Survival Outcomes Presented at ISCT
19/07/21		178.27KB	Share
MSB COVID ARDS Trial Respiratory Outcomes Presented
16/07/21		168.08KB	Share
MSB COVID ARDS Trial Results Presentation
16/07/21		2.87MB	Share
MSB Appendix 3Y - Change of Director's Interest Notice
14/07/21		279.52KB	Share
MSB Appendix 3G
07/07/21		382.66KB	Share
MSB Mesoblast Update on Chronic Low Back Pain Program
01/07/21	PRICE SENSITIVE	181.33KB	Share
MSB MSB Reports Q3 Financial Results and Operational Highlight
03/06/21	PRICE SENSITIVE	479.65KB	Share
MSB Third Quarter Results Presentation
03/06/21		2.01MB	Share
MSB Third Quarter Financial Results on Form 6-K
03/06/21	PRICE SENSITIVE	633.63KB	Share
MSB Mesoblast Q3 Financial Results Webcast
03/06/21		128.45KB	Share
MSB Remestemcel-L for COPD Published in Respiratory Research
25/05/21		167.73KB	Share
MSB COVID ARDS Trial Topline 60-Day Results
30/04/21	PRICE SENSITIVE	191.36KB	Share
MSB Appendix 4C Quarterly Activity Report
30/04/21	PRICE SENSITIVE	368.8KB	Share
MSB Mesoblast Corporate Update Webcast
30/04/21		151.83KB	Share
MSB Director's Interest Notice - Appendix 3X
06/04/21		218.38KB	Share
MSB Mesoblast Operational Highlights and Upcoming Milestones
31/03/21		198.71KB	Share
MSB Director Appointment/Resignation
29/03/21		172.63KB	Share
MSB Prospectus for Warrants in Connection with US$110M Raise
15/03/21		572.99KB	Share
MSB MSB Closes US$110M Raise Led By US Strategic Investor Group
09/03/21		190.16KB	Share
MSB Cleansing Notice and Appendix 2A
09/03/21		438.01KB	Share
MSB Cleansing Notice and Appendix 2A
03/03/21		525.01KB	Share
MSB Proposed issue of Securities - MSB
02/03/21		27.96KB	Share
MSB Mesoblast Raises US$110M Led By US Strategic Investor Group
02/03/21	PRICE SENSITIVE	195.87KB	Share
MSB Half Year Report and Accounts (including Appendix 4D)
26/02/21	PRICE SENSITIVE	806.09KB	Share
MSB Trading Halt
26/02/21	PRICE SENSITIVE	206.93KB	Share
MSB Remestemcel-L for COVID-19 MIS-C published in Pediatrics
17/02/21		192.67KB	Share
MSB Mesoblast Phase 3 Chronic Low Back Pain Results
11/02/21	PRICE SENSITIVE	360.41KB	Share
MSB Mesoblast Corporate Update Webcast
11/02/21		178.83KB	Share
MSB Appendix 4C Quarterly Activity Report
29/01/21	PRICE SENSITIVE	209.47KB	Share
MSB CHF Phase 3 Trial Results Presented at Investor Conference
12/01/21		120.14KB	Share
MSB Mesoblast Healthcare Conference Investor Presentation
12/01/21		1.59MB	Share
MSB Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF
11/01/21	PRICE SENSITIVE	126.77KB	Share
MSB Mesoblast Webcast
18/12/20		106.41KB	Share
MSB Mesoblast Update on COVID-19 ARDS Trial
18/12/20	PRICE SENSITIVE	106.84KB	Share
MSB Trading halt
16/12/20	PRICE SENSITIVE	155.18KB	Share
MSB Pause in Trading
16/12/20	PRICE SENSITIVE	116.28KB	Share
MSB Mesoblast Phase 3 Chronic Heart Failure Results
15/12/20	PRICE SENSITIVE	130.08KB	Share
MSB Mesoblast Corporate Update Webcast
15/12/20		105.09KB	Share
MSB Remestemcel-L Reduces Biomarkers for Mortality in SR-aGVHD
07/12/20		146.6KB	Share
MSB Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS
02/12/20	PRICE SENSITIVE	116.21KB	Share
MSB Appendix 2A
27/11/20		167.16KB	Share
MSB Results of Meeting
24/11/20		208.38KB	Share
MSB CEO Presentation to 2020 Annual General Meeting
24/11/20		1.7MB	Share
MSB Mesoblast Chairman Message to 2020 AGM
24/11/20		113.7KB	Share
MSB Novartis and Mesoblast Remestemcel-L Collaboration
20/11/20	PRICE SENSITIVE	147.21KB	Share
MSB First Quarter Results Presentation
20/11/20	PRICE SENSITIVE	2.18MB	Share
MSB MSB Q1 Financial Results and Operational Highlights
20/11/20	PRICE SENSITIVE	271.6KB	Share
MSB First Quarter Financial Results on Form 6-K
20/11/20	PRICE SENSITIVE	590.73KB	Share
MSB Mesoblast Corporate Update and Financial Results Webcast
20/11/20		81.67KB	Share
MSB DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial
11/11/20	PRICE SENSITIVE	117.63KB	Share
MSB COVID-19 ARDS & GVHD Update, Quarterly Report & Appendix 4C
29/10/20	PRICE SENSITIVE	192.37KB	Share
MSB Annual Report to shareholders
26/10/20		3.05MB	Share
MSB Notice of Annual General Meeting and Proxy Form
26/10/20		357.21KB	Share
MSB Appendix 4G and Corporate Governance Statement
26/10/20		202.52KB	Share
MSB Remestemcel Controlled Study in Crohns & Ulcerative Colitis
22/10/20		126.07KB	Share

REFRESH

First 2 3 4 5 6

(20min delay)
Last $1.19		Change -0.020(1.65%)		Mkt cap ! $1.364B

Open	High	Low	Value	Volume
$1.21	$1.21	$1.18	$750.8K	629.6K

Buyers (Bids)

No.	Vol.	Price($)
13	119869	$1.19

Sellers (Offers)

Price($)	Vol.	No.
$1.20	21641	6

View Market Depth

No.	Vol.	Price($)
9	113405	1.185
9	55193	1.180
11	144584	1.175
6	48214	1.170
2	8550	1.165

Price($)	Vol.	No.
1.190	14881	4
1.195	31486	7
1.200	24340	14
1.205	61604	6
1.210	125885	16

Last trade - 11.00am 02/10/2024 (20 minute delay)


Last $1.19		Change -0.020 ( 1.31 %)
Open	High	Low	Volume
$1.21	$1.21	$1.19	106890
Last updated 11.19am 02/10/2024 ?

MSB (ASX) Chart

MESOBLAST LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories